LOXO-292 shows 68% ORR, sustained durability in heavily pretreated RET fusion-positive NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Eli Lilly and Co. presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login